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CARDIOPULMONARY BYPASS, MYOCARDIAL 
MANAGEMENT, AND SUPPORT TECHNIQUES 
MOLECULAR 
CARDIOMYOPLASTY: 
POTENTIAL CARDIAC GENE 
THERAPY FOR CHRONIC 
HEART FAILURE 
In this study, we evaluated the feasibility of converting cardiac fibroblasts into 
skeletal muscle cells by forced expression of the MyoD gene, one of the basic 
helix-loop-helix myogenic factors. Primary cardiac fibroblasts, isolated from new- 
born rats, were infected with retrovirus-carrying sense or antisense MyoD gene. Ten 
days after infection, expression of MyoD protein was demonstrated in 95% of cells 
infected with sense MyoD virus by intense nuclear immunostaining with a MyoD 
polyclonal antibody. In contrast, none of the cells infected with antisense MyoD 
virus showed staining. On withdrawal of serum, 95% of MyoD positive cells became 
elongated and, in the presence of appropriate cell density, fused to form multinu- 
cleated myotubes, morphologically similar to striated muscle cell. Expression of 
downstream myogenic differentiation markers, myosin heavy chain and myocyte- 
specific enhancer factor 2, in 95% of these myotubes were detected by intense 
cytoplasmic and nuclear immunostaining, respectively, with specific antibodies. In 
contrast, no detectable staining was noted in MyoD negative cells. Spontaneous 
contractile movements were noted in a few clusters of myotubes. In summary, 
cardiac fibroblasts were able to be converted into bonafide potentially functional 
skeletal myocytes as shown by definitive morphologic and biochemical changes. 
Further studies with in vivo models are needed to explore this unique molecular 
strategy to treat patients with chronic heart failure. (J THORAC CARDIOVASC SURG 
1995;109:918-24) 
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0 ardiomyoplasty is an operation consisting of wrapping synchronously paced transformed fa- 
tigue-resistant skeletal muscle, commonly the latis- 
simus dorsi, around the heart. The operation offers 
a potential therapy for chronic heart failure, by 
using the power derived from skeletal muscle. 1'2 
Another strategy to treat patients with heart failure 
is to provide additional endogenous power, that is, 
more cardiac myocytes. However, mammalian car- 
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diac myocytes become terminally differentiated and 
lose their ability to undergo mitosis soon after the 
newborn period. 3'4 The mechanism responsible 
for this cell cycle arrest is largely unknown. As a 
result, we have few clues as to how to induce 
cardiac myocytes to reenter the cell cycle. In 
addition, because possible cardiac myogenic 
facters have not been identified, conversion of 
cardiac nonmuscle cells to cardiac myocytes is 
currently impossible. 
In skeletal muscle, myogenic transcription factors, 
the MyoD family of basic helix-loop-helix proteins, 
are known to function as toaster genes for induction 
of the skeletal muscle differentiation program. 5 Ex- 
pression of transfected MyoD gene has been shown 
to mediate the conversion of mouse C3H10T1/2 
fibroblast cell line into stable myoblast, which could 
be induced to undergo terminal differentiation i to 
multinucleated myotubes, morphologically similar 
to skeletal muscle cells. 6 Biochemically, in addition 
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to myosin heavy chain (MHC), MyoD is known to 
induce the expression of other downstream myo- 
genic differentiation markers, like myocyte-specific 
enhancer factor 2 (MEF2). 7 Because ssentially the 
same structural contractile apparatus is shared by 
both cardiac and skeletal myocytes, conversion of 
cardiac fibroblasts, for example, those in a scar after 
rnyocardial infarction, into potentially functional 
skeletal myocytes rnay be of benefit for the treat- 
ment of heart failure. In this study, we evaluated the 
feasibility of converting cardiac fibroblasts into skel- 
etal rnuscle cells by forced expression of the MyoD 
gene in primary cultured cardiac fibroblasts. 
Materials and methods 
Isolation of cardiac fibroblasts. Primary cardiae fibro- 
blasts were prepared from newborn rat ventricles. Hearts 
were removed from 1-day-old newborn Wistar rats. The 
ventricles were washed with 4°C balanced salt solution 
(MgSO4" 7H20 200 mg/L, NaC1 68 gin/L, KC1 400 mg/L, 
NaH2PO4.H20 1.5 gm/L, glucose 1 gin/L, and HEPES 
buffer, pH 7.5, 4.76 gin/L). They were then minced into 
fine fragments and again washed with 4 ° C balanced salt 
solution. The ventricular tissue was transferred into a 50 
ml tube eontaining 3 to 5 ml balanced salt solution, with 
0.01% collagenase II and 0.5% pancreatin, and incubated 
in 37 ° C with gentle agitation for 10 to 15 minutes. The 
supernatant was added to 1.5 ml of fetal calf serum (FCS). 
After 5 to 6 cycles of digestion, the supernatant was 
pooled and centrifuged at 500 to 800 rpm for 5 minutes. 
The pellet was resuspended in growth medium (20% FCS 
in Dulbecco's modified Eagle's medium [DMEM]) and 
plated at 100 cells/mm 2 in each 100 × 20 mm uncoated 
plastie Petri dishes. The supernatant was aspirated and 
discarded after 15 to 20 minutes of incubation at 37 ° C to 
get rid of unattached cells. The fibroblasts were then 
maintained in growth medium. 
All animals received humane care in eompliance with 
the "Principles of Laboratory Animal Care" formulated 
by the National Society for Medical Research and the 
"Guide for the Care and Use of Laboratory Animals" 
prepared by the Institute of Laboratory Animal Resources 
and published by the National Institutes of Health (NIH 
Publication No. 86-23, revised 1985). 
Viral propagation and cell infection. Amphotropic ret- 
rovirus-producing cell lines generated with PA317 cells 
were obtained from Dr. D. Miller. 8 These cell lines 
produced retroviruses that carry neomycin G418 resis- 
tance gene and sense or antisense MyoD gene. The 
virus-producing cells were maintained in growth medium 
(20% FCS DMEM). Viral infection of fibroblasts was 
performed as described by Weintraub and assoeiates. 8 
After 3 days, infected cells were selected by adding 
neomycin G418 in a eoncentration f 500 ~g/ml (Gibco, 
Grand Island, N.Y.) to the medium. Seven days after 
neomycin G418 seleetion, serum was withdrawn by chang- 
ing the medium to 1% FCS DMEM. After 1 to 2 weeks, 
the eells were examined for morphologic changes by phase 
contrast microscopy by means of Zeiss objeetives (Carl 
Zeiss, Inc., Thornwood, N.Y.). 
Immunotluoreseence. Cells were fixed by direct immer- 
sion in 3.7% paraformaldehyde in phosphate-buffered 
saline for 10 minutes. Fixed cells were then made perme- 
able by immersion in 0.3% Triton X100 octyphenoxy 
polyethoxyethanol i  phosphate-buffered saline for 5 min- 
utes, washed three times with phosphate-buffered saline, 
and incubated with specific antibodies. Primary antibodies 
used for immunofluorescence w re MF2o monoclonal 
anti-MHC antibody, rabbit polyclonal anti-MEF2, and 
anti-MyoD äntibodies. The secondary antibodies used 
were rhodamine-conjugated goat antimouse immuno- 
globulin G and fluorescein isothiocyanate-conjugated 
goat antirabbit immunoglobulin G (Boehringer, In- 
gelheim Corp., Indianapolis, Ind.). Cells were examined 
by immunofluorescent microscopy with a Zeiss 63x 
objective. 
Results 
Morphologic ehanges. Between 1 and 2 weeks 
after the withdrawal of serum, the cell structure was 
exarnined by phase contrast microscopy. As shown 
in Fig. 1, A, 95% of the fibroblasts infected with 
sense MyoD virus had become elongated and, in 
the presence of appropriate cell density, fused to 
form rnultinucleated cells (rnyotubes). In contrast, 
all cells infected with antisense MyoD virus re- 
rnained round and unchanged, as shown in Fig. 1, 
B. The differences in morphologic details were 
demonstrated in higher magnification (63×) as 
shown in Fig. 2, A and B. The fused rnyotube (Fig. 
2, A) with its elongated cell body and rnultiple 
nuclei is rnorphologically sirnilar to striated mus- 
cle fibers, whereas the control cells (Fig. 2, B), 
infected with antisense MyoD virus, remained 
unchanged. 
A few clusters of rnyotubes were observed to have 
spontaneous contractions under the eulture condi- 
tions described herein, suggesting that these con- 
verted myotubes had intact contractile rnachinery. 
Further studies with physiologic conditions and 
stimuli are needed. 
Bioehemical changes. Ten days after infection, 
expression of MyoD protein was dernonstrated in
95% of fibroblasts infected with sense MyoD virus 
by intense imrnunostaining with anti-MyoD anti- 
body. In contrast, none of the cells infected with 
antisense MyoD virus showed staining (data not 
shown). Double immunostaining for the presence of 
known downstream MyoD-inducible myogenic dif- 
ferentiation markers, MHC and MEF2, 7 was per- 
formed 1 to 2 weeks after serum withdrawal (i.e., 2 
to 3 weeks after infection), at the time when there 
were rnarked rnorphologic hanges with the sense 
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Fig. 1. Morphologic analysis of primary cardiac fibroblasts infected with sense or antisense MyoD virus by 
phase contrast microscopy. This analysis was performed 1 to 2 weeks after the withdrawal of serum. A, 
Magnification (x40) of cardiac fibroblasts, which were converted into myotubes after sense MyoD virus 
infection. B, Magnification (x40) of cardiac fibroblasts, which remained unchanged after antisense MyoD 
virus infection. 
MyoD virus-infected cells. As depicted in Fig. 2, C, 
the elongated sense MyoD virus-infected cell (the 
same frame as in Fig. 2, A) expressed abundant 
downstream myogenic differentiation markers, 
MHC (red) in its cytoplasm and MEF2 (green) in its 
nuclei. The pattern of cytoplasmic MHC staining 
suggested the presence of striation. These definitive 
biochemical changes demonstrated that the myo- 
genic differentiation program has been induced. In 
contrast, the antisense MyoD virus-infected cells 
(Fig. 2, D, same frame as in Fig. 2, B) failed to turn 
on the myogenic differentiation program by having 
no staining, indicating the absence of MHC and 
MEF2 protein. 
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Fig. 2. Combined morphologic and immunofluorescent a alysis of primary cardiac fibroblast infected with 
sense or antisense MyoD virus. This analysis was performed 1 to 2 weeks after the withdrawal of serum. 
A, Phase contrast microscopy at 63× magnification offibroblasts that were converted to myotube by sense 
MyoD virus infection. Note the cell shape and multiple nuclei. B, Phase contrast microscopy at 63× 
magnification of fibroblast that remained unchanged by antisense MyoD virus infection. 
Discussion 
Chronic congestive heart failure has emerged as 
an important public health problem. According to 
the resour¢es of the Rochester Epidemiology 
Project 9and the current population estimate of 260 
million in the United States, m the annual incidence 
of ¢hronic congestive h art failure is about 300,000, 
with the overall prevalence being about 650,000. 
The overall prognosis is poor and has shown mini- 
mal improvements, with 80% survival at 3 months 
after diagnosis and 66% at 1 year, 11 despite proven 
efficacy of newer therapies like vasodilators. 12Sur- 
gical therapy for chronic heart failure includes organ 
transplantation and dynamic cardiomyoplasty. Or- 
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Fig. 2. Cont'd. C, Immunofluorescent microscopy at 63× magnification of the same fibroblasts as in A, 
which were converted to multinucleated myotube by sense MyoD virus infection. Primary antibodies used 
included specific anti-MEF2 and anti-MHC antibodies. Because rhodamine-conjugated goat antimouse 
secondary antibody was used, the presence of MHC, a cytoplasmic protein, will appear ed. Where 
fluorescein isothiocyanate-conjugated goatantirabbit secondary antibody was used, the presence of 
MEF2, a nuclear transcription factor, will appear green. Note the hint of red cytoplasmic striation. D, 
Immunofluorescent microscopy at 63× magnification fthe same fibroblasts as in B. No staining was noted, 
indicating the absence of both MHC and MEF2 protein. 
gan transplantation is currcntly plagued by lack of 
donor availability, immunosuppression a d rejec- 
tion, and graft atherosclerosis. Early clinical hemo- 
dynamic results with dynamic ardiomyoplasty were 
encouraging, but long-term survival studies are lack- 
ing.13, 14 More recently, cell transplantation with 
mouse fetal cardiac myocytes, in an attempt to 
restore cardiac function, indicated that donor cells 
were stably incorporated into the recipient heart 
and that there appeared to be nascent intercalated 
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disks between donor and recipient myocytes. 15How- 
ever, problems with fetal cell availability make this 
approach impractical. A more applicable strategy to 
restore cardiac function is to convert cardiac fibro- 
blasts into contracting muscle cells. However, car- 
diac myogenic factors that are needed to induce 
"cardiac regeneration" have not been identified. In 
contrast, skeletal myogenic factors, the MyoD fam- 
ily of basic helix-loop-helix proteins, have been well 
described. » Because essentially the same structural 
contractile apparatus is shared by both cardiac and 
skeletal myocytes, conversion of cardiac fibroblasts, 
for example, those in a scar after myocardial infarc- 
tion, into potentially functional skeletal myocytes 
may be of benefit for the treatment of heart failure. 
This study shows that freshly cultured primary car- 
diac fibroblasts can be converted into skeletal myo- 
cytes as indicated by definitive morphologic and 
biochemical parameters and represents the first step 
in evaluating this new molecular strategy to restore 
cardiac function. The potential that these converted 
myocytes may be functional was suggested by the 
presence of spontaneous contractions in a few clus- 
ters of these cells. In vitro smdy to elucidate condi- 
tions needed for paced contractions of these con- 
verted cells is currently being evaluated. In vivo 
models will be used to further evaluate the feasi- 
bility and the efficiency of converting fibroblasts 
into myocytes and its physiologic consequences. 
In addition, studies to develop safe and efficient 
technique of gene delivery into the myocardium 
are ongoing. 
We thank Dr. D. Miller, University of Washington, 
Seattle, for providing the virus-producing cell lines. 
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Discussion 
Dr. George J. Magovern (Pittsburgh, Pa.). In 1989 we 
submitted an abstract to The So¢iety of Thora¢ic Surgeons 
forum (unfortunately not accepted) that described a dif- 
ferent approach to the same idea. We were able to isolate 
satellite cells from a skeletal muscle fiber. We grew those 
satellite cells in culture and labeled them with thymidine. 
We then performed a cryoinjury to the heart, injected 
these cells, and were able to obtain biopsy tissue from that 
area 6 weeks after implantation. 
It appeared to us that indeed the thymidine-labeled 
satellite cell, which is embedded in cardiac muscle fiber, 
appears to be growing into intercalated disk. We thought 
that perhaps the skeletal muscle satellite cell was actually 
forming cardiac cells, myoblasts. In other words, in the 
milieu of the heart with the electrical stimulus over a 
period of time, a satellite cell of the skeletal muscle, being 
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a stem cell, might grow into a cardiac cell rather than a 
skeletal muscle cell. 
Dr. Tam. Certainly the ultimate goal is to regenerate 
the cardiac muscle cell itself. I do not know of any 
evidence or suggestion that the environment of the heart 
can induce skeletal muscle cell transformation i to car- 
diac musele cells. 
As I am sure you are aware, an article just published in 
Science 15 described fetal cardiac muscle cell transplanta- 
tion. In that case the authors thought hey saw interca- 
lated disk formed between the transplanted cells and the 
native cells. In that case they need more study to see if 
these cells are actually functional. 
Dr. Magovern. We did show intercalated isk in this 
area, and subsequent work by Dr. Gaugh confirmed that 
the gene, the lax gene, was present in these cells. We think 
it is possible that a skeletal muscle satellite cell in the 
heart can develop into a cardiac myocyte. 
Dr. Thoralf M. Sundt (Harefield, England). It is my 
understanding that one of the difficulties with gene ther- 
apy is the stability of the transferred gene. You have 
demonstrated vidence of expression of protein products 
in the transfected cells, but do you have any direct 
evidence regarding the long-term stability of the trans- 
ferred genes themselves in those cells? Of course, stability 
of that gene may not be neeessary, because once the 
differentiation is initiated the signal proteins may not be 
required further. That would be a significant advantage to 
your approach. Do you have any comments or data 
regarding this? 
Dr. Tam. Yes, in fact, you are right. The MyoD gene is 
actually a gene that only needed to be expressed for a 
short time. In fact, once it turned on the muscle differen- 
tiated program, the cell continues to express muscle 
differentiated phenotype. In this instance, long-term ex- 
pression of the gene is not critical. 
Mr. Magdi H. Yacoub (London, England). Are you 
optimistic to apply similar techniques to myocardium 
knowing that the myocardial cell is quite different from 
the skeletal cell with regard to the genetic omposition? 
This is particularly true in the total absence of a transcrip- 
tion factor like MyoD, which would govern the transfor- 
mation of the muscle. 
Dr. Tam. It certainly is not an ideal approach. The 
reason we took this approach is that we have not yet 
identified cardiac type myogenic factors. 
There is no evidence at this time that these skeletal 
muscle cells will be functional in the heart in terms of 
contraction. One notion is that the presence of skeletal 
muscle cells may impede further dilation of the heart, and 
that may be another way that this process may help. I 
agree with you that we are far from regenerating a heart. 
